2025 Key Updates in Science and Policy

Picture of Patrick Wang

Patrick Wang

Expert of Peptides | Ask me anything about Peptides | Sales Manager at AHB Lab
Cover

Table of Contents

From recent advances to challenges and ethical dilemmas that shape the scientific landscape, this article encompasses it all-from the intersection of science and policy. We cover all aspects, from AlphaFold3’s release of revolutionary AI code and the disturbing reproducibility crisis in biomedical research to the lapses in financial conflict disclosures and changes in public health and environmental policies. In addition, we discuss how research chimpanzees are being moved to sanctuaries and also a rather exciting cosmic find dealing with galaxies coming in pairs. Taken altogether, each of these news items provides quite the broad vision of challenging interactions among innovation, regulation, and society.

 

AlphaFold3 Code Released: A Breakthrough for Protein Prediction

In a long-awaited move, Google DeepMind just released the code for its super-advanced artificial intelligence software called AlphaFold3. Immediately, excitement erupted across the research community. AlphaFold3 was announced in Nature on May 8 for being able to predict protein structures and interactions with DNA, RNA, and other proteins in a way no other program has ever done-a major advance toward drug discovery and other scientific uses.

But that code was finally released more than six months after the presentation, to the frustration of many researchers. Critics said at that time that a lack of immediate access impeded reproducibility with only pseudocode and limited-use online portal available at that time. Now, on November 11, DeepMind released the complete code and model weights for non-commercial uses to allow the researchers to replicate the findings and build on them. The company also emphasized that at least a few groups had already reproduced AlphaFold3 from the pseudocode, itself demonstrating the reproducibility of the Nature paper.

 

Biomedical Studies Face Reproducibility Crisis

A recent global survey of biomedical research has exposed a disturbing trend: replication failures. Published in PLOS Biology, the survey of 1,630 biomedical scientists included 880 who said they had attempted to replicate another researcher’s work. Shockingly, 724 of those attempts failed, and nearly one-fourth of respondents admitted they couldn’t reproduce their own experiments.

This survey underlines a wider problem: 72% of those responding to the survey agreed there was a reproducibility crisis in the field. Scientists said that intense pressure to publish along with a lack of institutional and funding support are key drivers of irreproducible studies into journals. These findings really echo a 2016 survey in Nature that reported similar concerns across multiple scientific disciplines.

 

Financial Conflicts in Research Often Go Unflagged

A new study has exposed a surprising gap in the way financial conflicts of interest are disclosed in life sciences research. Published in PLOS ONE, the analysis examined 3,888 articles from 40 high-impact journals published in 2021 and 2022. The surprise conclusion: only 30% of the articles disclosed potential conflicts of interest, and just half of those disclosures were flagged in the National Institutes of Health’s PubMed database.

Since 2017, PubMed has had a field for conflict-of-interest statements, in hopes of making those disclosures more transparent. But the study found that many journals don’t use the feature very well. In an expanded analysis including 7,000 journals, just one-third submitted conflict-of-interest statements to PubMed – a factor some scientists consider important to the transparency and accountability of science publishing.

 

Public Health Under Scrutiny: RFK Jr.’s Potential Impact

As Donald Trump gets to work, one of his first moves is to embolden a vaccine skeptic: Robert F. Kennedy Jr. The public health world goes into high alert. This is an environmental lawyer whose past proposals have included banning fluoride from public water supplies and dismantling key departments of the FDA. Lawrence Gostin, a specialist in public health law, describes this as “the darkest day for public health and science in my lifetime.”

While the FDA and CDC enjoy a degree of independence from federal agencies, Kennedy’s presence has the potential to blow vaccine policy off course and undermine confidence in public health measures. Public health systems operating at the state level might struggle to hang onto evidence-based vaccination mandates. Experts caution that this erosion of trust in public health guidance is going to continue, with the consequence of complicating efforts to address the pressing health challenges even further.

 

Trump’s EPA Pick: Deregulation on the Horizon

President-elect Trump made a choice to lead the EPA that elicited sharp reactions. Now he’s nominated Lee Zeldin, the former New York congressman, to helm the agency. Zeldin has been known for his deregulatory position and recently promised to “unleash American businesses” with environmental protection rollbacks.

Environmental watchdog groups sound the alarm, pointing to Zeldin’s abysmal environmental voting record as their prime argument while in Congress. His nomination presages a rule of weakened critical climate policies and increased political interference in research programs at the EPA, says an advisory group; such actions warn of far-reaching ramifications on environmental health and safety.

 

Chimps Relocated to Sanctuary After Longstanding Debate

The U.S. National Institutes of Health said it will relocate 23 retired research chimpanzees from a New Mexico facility to the Chimp Haven sanctuary in Louisiana. The move is in line with major steps toward ending invasive biomedical research on chimpanzees, which NIH officially declared over in 2015.

The decision comes after years of controversy. In 2019, NIH ruled too many chimps were too old or ill to move-a decision that generated outrage among animal welfare activists. Questions about staffing at the current facility ultimately proved the catalyst for the agency’s change of heart. Chimp Haven expects the first arrivals to begin in early 2025 and plans other transfers for research chimps.

 

Stroke Researcher Takes Leave Amid Misconduct Allegations

Prominent Alzheimer’s and stroke researcher Berislav Zlokovic has been put on indefinite leave from the University of Southern California amid allegations of research misconduct. A year-long Science investigation found in many quarters a broad-spectrum concern about work overseen by Zlokovic, which has already caused a $30 million clinical trial to be canceled for a stroke drug candidate he helped develop.

Furthermore, the case required USC to refund approximately $2 million in funding allocated for the trial from the U.S. National Institutes of Health. The case sheds light on how challenging it is yet to maintain integrity in research, especially in high-stakes research, such as biomedical research.

 

Cosmic Discovery: Dual Galaxies Create Compound Lens

Astronomers have caught a rare cosmic alignment-two lined-up galaxies commanding a compound gravitational lens. This peculiar configuration distorts and magnifies light coming from a distant quasar, a super-massive black hole spewing intense radiation.

In a new work, using NASA’s James Webb Space Telescope and many other instruments, they studied six sharp images of the quasar, magnified up to 40 times. The zigzag path the light takes around the galaxies marks out a new tool for measuring the rate of expansion and history of the universe. The results are yet to be peer-reviewed and have been released as a preprint on arXiv. The study could have far-reaching implications for cosmology and the nature of dark matter.

 

Conclusion

This eclectic mix of stories about scientific and policy developments underlines the opportunities and challenges that face both researchers and policymakers in this week’s news. Tales of artificial intelligence advances, juxtaposed with ethical dilemmas and public health, raise a number of questions with regard to innovation, regulation, and societal consequence.

At AHB Lab, we’re dedicated to keeping you updated on these pivotal developments and their implications for our industry. Stay connected for more insights!

Leave a Reply

Your email address will not be published. Required fields are marked *

公司最新訊息

科學定義年輕:打破濃度天花板,突破 50 倍胜肽的微觀保養新標準

迷思破解:你臉上敷的是保養品,還是昂貴的「安慰劑」? 看著鏡子裡的自己,你是否也曾陷入「只要表面沒有皺紋,就是年輕」的迷思?你是否花了大筆預算購買頂級抗老精華,擦了大半年卻發現保養效果總是陷入停滯 ?  許多品牌與消費者花費大筆金錢,卻彷彿只是在臉上塗了一層「昂貴保鮮膜」,這種「食之無味,棄之可惜」的瓶頸,是許多消費者與品牌端共同的痛點。 其實,真正的年輕從來不是表面看起來沒有皺紋,而是細胞正在健康、充滿活力地運作,你每天精心塗抹的,很可能只是一劑帶來心理安慰的「安慰劑」。 關鍵往往不在於產品「有沒有加」抗老成分,而在於「有沒有達到有效濃度」。 濃度即是真理:為什麼傳統胜肽經常淪為微弱的 Wi-Fi? 為了理解這個現象,我們必須從胜肽的製造工藝說起 。 傳統的抗老胜肽大多仰賴化學合成,其原料成本極其高昂,在巨大的成本壓力下,市面上多數保養品所使用的胜肽原料濃度往往只有 100 ppm,經過常規稀釋加進產品後,真正作用在皮膚上的只剩下微乎其微的 10 ppm。 這 10 ppm 的微弱訊號就像隨時會斷線的 Wi-Fi,根本無法穿透皮膚防火牆去啟動細胞修復。 當「兵力」不夠,面對成千上萬的老化細胞,低濃度保養幾乎等同於白做工,然而,最新的生技突破為這場微觀災難帶來了轉機。 AHB Lab 透過先進的細胞級生物工程與獨家的微生物發酵平台,成功研發出「第3代生物合成肽」,一舉突破傳統化學合成的成本極限,這項技術將原料濃度強勢拉高到驚人的 5000

Read More
公司最新訊息

為什麼傳統控糖策略總是陷入瓶頸?揭開「定序 9 胜肽」突破停滯期的細胞級密碼

當鑰匙過剩,而鎖卻壞了 在現代代謝健康管理中,許多患者與醫療專業人員面臨著一個共同的挫折:為什麼藥越吃越重,血糖卻依然像脫韁野馬一樣失控? 傳統的思維往往認為,只要乖乖吞下藥丸,強制刺激身體分泌更多的「胰島素」,數字總有一天會降下來 。然而,第二型糖尿病最殘酷的現實是,患者體內根本不缺胰島素這把「鑰匙」,而是細胞表面負責接收訊號的「鎖」壞掉了,這就是醫學上常說的「胰島素阻抗」。 當這把鎖壞了,糖分通道的大門緊閉,製造再多鑰匙也打不開大門,導致葡萄糖死死堵在血管裡,而細胞卻在極度挨餓 。更糟的是,長期依賴單一機制強制壓低數字,不僅無法修復細胞受損的接收器,還可能讓患者承受肝腎負擔加重的無形恐懼,甚至面臨瞬間失去意識的低血糖暈眩風險 。 有沒有一種方法,能夠不依賴傳統的「暴力壓制」,而是從細胞根源溫和且精準地重啟代謝通道?答案,就藏在尖端生物科技的「胜肽(Peptide)」技術中 。 什麼是「定序 9 胜肽」?它如何從細胞根源解決問題? 為了解決這把「壞掉的鎖」,科學家們將目光轉向了天然植物胜肽。經過多年的心血,研發團隊成功從高達 320 公斤的特定品種苦瓜中,極致濃縮精煉出 1 公斤的活性能量,並成功解碼出一段分子量僅有 640 Da 的「定序 9 胜肽(苦瓜九肽)」。 這段微小胜肽在體內扮演著「超級備用鑰匙」的角色 。它具有極高的生物利用度(Bioavailability),能夠直接繞過細胞表面那把壞掉的鎖,強制啟動受器,精準推開緊閉的糖通道大門 。

Read More
公司最新訊息

為什麼吃再多苦瓜也降不了血糖?解密「苦瓜九肽」的科學真相與控糖未來

血糖失控的真相與苦瓜迷思 在台灣,糖尿病是一個影響著超過兩百萬人的嚴重健康問題 。面對居高不下的血糖數字,許多人經常尋求民間偏方,其中最常見的巨大迷思就是:「吃苦瓜就能降血糖嗎?」 。 答案是:錯的! 如果您或您的消費者只是單純地大量食用苦瓜,不僅有效成分極難被人體吸收,攝取過多的苦瓜纖維甚至會被轉換為醣類,導致血糖不降反升 。單純吃天然食物與實現真正的「醫療級改善」,這中間存在著巨大的科學鴻溝。今天,我們將從生物機制的底層邏輯出發,為您揭開血糖失控的真相,並探討科學界如何透過先進的生技技術,真正利用苦瓜胜肽來逆轉這個局面。 為什麼傳統苦瓜萃取物無效? 要理解市售產品為何無效,我們必須先釐清細胞代謝的底層邏輯。 核心機制:胰島素阻抗的「鎖與鑰匙」 當我們進食後,食物會轉化為葡萄糖進入血管,導致血糖升高 。此時,胰臟會分泌一種稱為「胰島素」的激素 。 在細胞生物學中,這是一個優雅的機制: 鑰匙:您可以把胰島素想像成一把鑰匙 。 鎖:在細胞表面,存在著被稱為「胰島素受器」的鎖孔 。 開門:當鑰匙(胰島素)順利插入鎖(受器)時,會發出訊號,打開旁邊的「糖通道」大門 。血管裡的葡萄糖便能順利進入細胞轉化為能量,血糖自然就會下降 。 然而,對於第二型糖尿病患者而言,問題不在於缺乏鑰匙(胰島素分泌足夠),而是「鎖(受器)壞掉了」 。這在醫學上被定義為「胰島素阻抗」 。因為鎖壞了,糖通道的大門打不開,導致葡萄糖全部阻塞在血管中,造成血糖居高不下,而細胞本身卻處於挨餓狀態 。

Read More